In this study, we measured the cell viability and cancer apoptosis event of currently-used HDACi in clinic on breast cancers, with the result that both Panobinostat and Belinostat have great potential for application in TNBC and HER2-enriched subtype breast cancer therapy, without cytotoxicity on normal breast epithelia cells. This evidence concerns the gene ERBB2 and breast carcinoma.